2 weeks Ago By Defense World Staff
Prudential Financial Inc. cut its holdings in Progyny, Inc. ( NASDAQ:PGNY – Free Report ) by 7.
6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 75,945 shares of the company’s stock after selling 6,214 shares during the quarter. Prudential Financial Inc.
owned about 0.09% of Progyny worth $1,310,000 as of its most recent SEC filing. A number of other institutional investors and hedge funds also recently bought and sold shares of the business.
GAMMA Investing LLC raised its holdings in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after purchasing an additional 1,246 shares in the last quarter.
Signaturefd LLC grew its position in Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock worth $25,000 after buying an additional 1,355 shares during the last quarter.
Nisa Investment Advisors LLC increased its holdings in shares of Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after buying an additional 1,526 shares in the last quarter.
KBC Group NV lifted its position in shares of Progyny by 84.6% during the 4th quarter. KBC Group NV now owns 4,669 shares of the company’s stock valued at $81,000 after acquiring an additional 2,140 shares during the last quarter.
Finally, Entropy Technologies LP boosted its stake in shares of Progyny by 5.5% during the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company’s stock worth $826,000 after acquiring an additional 2,499 shares in the last quarter.
94.93% of the stock is owned by institutional investors and hedge funds. Wall Street Analyst Weigh In Several equities research analysts have recently commented on the company.
BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a report on Monday, March 31st. JPMorgan Chase & Co.
raised their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th.
Bank of America boosted their price target on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th.
Finally, Canaccord Genuity Group lifted their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, February 28th.
Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $23.64.
Progyny Price Performance Shares of NASDAQ PGNY opened at $22.60 on Friday. Progyny, Inc.
has a one year low of $13.39 and a one year high of $36.36.
The business’s 50-day moving average price is $22.19 and its two-hundred day moving average price is $18.50.
The company has a market capitalization of $1.93 billion, a P/E ratio of 38.97, a price-to-earnings-growth ratio of 2.
39 and a beta of 1.33. Progyny Profile ( Free Report ) Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States.
Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. Read More Five stocks we like better than Progyny Unveiling The Power Of VWAP: A Key Indicator For Traders Conagra Stock Could Thrive as Tariffs Hit Other Sectors How to Start Investing in Real Estate Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds What is the Dow Jones Industrial Average (DJIA)? Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy? Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter .
.
